EMAIL THIS PAGE TO A FRIEND

Biomaterials

Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.


PMID 25993015

Abstract

This study investigated the feasibility of the use of polymeric microparticles for sustained and local delivery of immunomodulatory antibodies in immunotherapy of cancer. Local delivery of potent immunomodulatory antibodies avoids unwanted systemic side effects while retaining their anti-tumor effects. Microparticles based on poly(lactic-co-hydroxymethyl-glycolic acid) (pLHMGA) and loaded with two distinct types of immunomodulatory antibodies (CTLA-4 antibody blocking inhibitory receptors on T cells or CD40 agonistic antibody stimulating dendritic cells) were prepared by double emulsion solvent evaporation technique. The obtained particles had a diameter of 12-15 μm to avoid engulfment by phagocytes and were slightly porous as shown by SEM analysis. The loading efficiency of the antibodies in the microparticles was >85%. The in vitro release profile of antiCD40 and antiCTLA-4 from microparticles showed a burst release of about 20% followed by a sustained release of the content up to 80% of the loading in around 30 days. The therapeutic efficacy of the microparticulate formulations was studied in colon carcinoma tumor model (MC-38). Mice bearing subcutaneous MC-38 tumors were treated with the same dose of immunomodulatory antibodies formulated either in incomplete Freund's adjuvant (IFA) or in microparticles. The antibody-loaded microparticles showed comparable therapeutic efficacy to the IFA formulation with no local adverse effects. The biodegradable microparticles were fully resorbed in vivo and no remnants of inflammatory depots as observed with IFA were present in the cured mice. Moreover the microparticles exhibited lower antibody serum levels in comparison with IFA formulations which lowers the probability of systemic adverse effects. In conclusion, pLHMGA microparticles are excellent delivery systems in providing long-lasting and non-toxic antibody therapy for immunotherapy of cancer.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

P2222
Potassium phosphate dibasic, meets USP testing specifications
HK2O4P
450200
Potassium phosphate dibasic, 99.95% trace metals basis
HK2O4P
P8281
Potassium phosphate dibasic, reagent grade, ≥98.0%
HK2O4P
60353
Potassium phosphate dibasic, anhydrous, for luminescence, for molecular biology, BioUltra, ≥99.0% (T)
HK2O4P
P8584
Potassium phosphate dibasic solution, 1.0 M
HK2O4P
S7907
Sodium phosphate dibasic, BioXtra, ≥99.0%
HNa2O4P
S3264
Sodium phosphate dibasic, for molecular biology, ≥98.5% (titration)
HNa2O4P
S5136
Sodium phosphate dibasic, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥99.0%
HNa2O4P
255793
Sodium phosphate dibasic, 99.95% trace metals basis
HNa2O4P
S0876
Sodium phosphate dibasic, ReagentPlus®, ≥99.0%
HNa2O4P
71636
Sodium phosphate dibasic, BioUltra, for molecular biology, ≥99.5% (T)
HNa2O4P
W239901
Sodium phosphate dibasic, 99%, FG
HNa2O4P
94046
Sodium phosphate dibasic solution, BioUltra, 0.5 M in H2O
HNa2O4P
RDD007
Sodium phosphate monobasic, anhydrous, free-flowing, Redi-Dri, ≥99.0%
H2NaO4P
S8282
Sodium phosphate monobasic, BioXtra, ≥99.0%
H2NaO4P
S3139
Sodium phosphate monobasic, BioReagent, for molecular biology, anhydrous, ≥98%
H2NaO4P
S5011
Sodium phosphate monobasic, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.0% (titration)
H2NaO4P
S2554
Sodium phosphate monobasic, meets USP testing specifications, anhydrous
H2NaO4P
229903
Sodium phosphate monobasic, 99.999% trace metals basis
H2NaO4P
S0751
Sodium phosphate monobasic, ReagentPlus®, ≥99.0%
H2NaO4P
74092
Sodium phosphate monobasic solution, BioUltra, 5 M in H2O
H2NaO4P